Dysbiosis (Gut Microbiome Imbalance)

Dysbiosis is the loss of a stable, diverse gut bacterial community and its replacement by a composition that promotes intestinal permeability and systemic inflammation. Carlos Lopez-Otin, Maria Blasco, Linda Partridge, Manuel Serrano and Guido Kroemer added it as the twelfth hallmark of aging in their January 2023 Cell review, alongside chronic inflammation, on the argument that it appears with age, accelerates aging when experimentally worsened, and can be modified [1].

Nabil Bosco and Mario Noti describe the human pattern as loss of Clostridiales and Bifidobacterium with enrichment of Proteobacteria and pathobionts such as Enterobacteriaceae [4]. The causal direction has been tested in mice: transplanting an aged microbiome into young germ-free animals produced intestinal inflammation, leakage of microbial products into the circulation, chronic low-grade inflammation and increased systemic T-cell activation, and depleting TNF-alpha genetically or with antibody prevented the age-related dysbiosis and the low-grade inflammation that followed [4].

The human survival data come from Tomasz Wilmanski and colleagues, who analysed gut microbiome and phenotype data from over 9,000 people aged 18 to 101 across three cohorts, including the Osteoporotic Fractures in Men cohort aged 78 to 98 with roughly 4 years of mortality follow-up [2][3]. Microbiomes became progressively more individual starting in mid-to-late adulthood. That drift toward a unique composition continued in healthy people over about 80 but was absent in less healthy ones. Retaining high Bacteroides dominance into old age, or scoring low on microbiome uniqueness, predicted decreased survival [2][3].

The inflammatory link is documented but thin. Cabirou Shintouo and Rose Njemini screened PubMed, Web of Science and Scopus and retrieved only 7 relevant animal or human studies [3]. In the single human study, Proteobacteria correlated positively with IL-6 and IL-8, while Ruminococcus lactaris correlated negatively with IL-8 [3]. Aged-type microbiota in animals tracked with higher IL-6, TNF-alpha and TGF-beta, and with activation of TLR2, NF-kB and mTOR [3].

What can move it: in the PREMOTE trial, Yifei Zhang and colleagues randomised 409 people with type 2 diabetes across 20 Chinese centres to berberine, probiotics, both, or placebo for 12 weeks. Berberine alone cut HbA1c by 0.99 percentage points (95% CI -1.16 to -0.83) against 0.59 in the placebo arm, P < 0.001, with accompanying changes in gut bacterial composition [5]. No trial has yet shown that correcting dysbiosis extends human lifespan.

The plain takeaway: dysbiosis is a real, measurable age-associated change with mouse causal evidence and human survival correlation, but the interventions remain diet-level and disease-level, not lifespan-level.